Table 1 Patient characteristics. Data are shown as numbers and per cent (%) or means ± standard deviation (SD) or median interquartile range (IQR)/range and in relation to daily dose MMF

N (%)

1 g (5)

2 g (21)

3 g (8)

Disease subtype (dcSSc/lcSSc)

12/22 (35/65)

0/5

9/12

3/5

Sex (females/males)

30/4 (88/12)

5/0

19/2

6/2

ANA positivity, of which

33 (97)

5

20

8

 ATA

8 (24)

1

5

2

 ARA

4 (12)

0

4

0

 PM-SCL (75 or 100)

10 (29)

3

4

3

MMF producer (Roche/Actavis/Sandoz)

8/24/2 (24/71/6)

1/4/0

4/16/1

3/4/1

 Lung fibrosis

21 (62)

4

10

7

 Skin fibrosis

8 (24)

8

0

 Combination of disease manifestations

5 (15)

1

3

1

Dysbiosis Index (1–5) (n = 27)

13/14 (48/52)

1/2

9/7

3/5

PPI (daily, sporadic, none)

26/2/6 (76/6/18)

5/0/0

16/1/4

5/1/2

CCB (daily, sporadic, none)

26/0/8 (76/0/24)

3/0/2

17/0/4

6/0/2

NSAID (daily, sporadic, none)

2/1/31 (6/3/91)

1/0/4

1/0/20

0/1/7

MUST (0, ≥ 1)

30/4 (88/12)

5/0

3/18

1/8

F-calprotectin pathological (yes/no)

14/20 (41/59)

3/2

9/12

2/6

Mean ± SD

Mean ± SD

Mean ± SD

Mean ± SD

Age (years)

58 (15)

62 (14)

59 (15)

51 (16)

Weight (kg)

73 (16)

70 (15)

71 (14)

80 (23)

EUSTAR Revised Activity Index

2.30 (1.48)

3.0 (1.8)

2.2 (1.6)

2.1 (1.1)

Leukocyte count (10⁹/L)

7.3 (2.6)

8.4 (4.2)

7.2 (2.3)

6.6 (2.3)

Lymphocyte count(10⁹/L)

1.4 (0.6)

1.7 (1.0)

1.4 (0.47)

1.7 (0.83)

Albumin (g/L)

42 (3.5)

40 (3.7)

42 (3.6)

44 (2.9)

eGFR (ml/min/1.73 m²)

76 (12)

66 (6.1)

76 (12)

83 (9.0)

Median (IQR)

Median (range)

Median (range)

Median (range)

Disease duration (years)*

4.9 (2.7–8.1)

4.8 (1.4–25)

5.8 (1.0–17)

3.7 (0.3–6.1)

Duration since SSc diagnosis (years)

3.5 (1.2–7.1)

3.6 (1.0–9.8)

4.3 (0.0–18)

1.2 (0.7–10)

Duration of MMF treatment (years)

2.1 (1.1–4.3)

2.5 (0.8–9.5)

2.6 (0.3–6.9)

0.9 (0.5–9.3)

Faecal calprotectin

39 (12–102)

74 (32–194)

41 (4–443)

17 (1–201)

UCLA SCTC GIT 2.0 Total score (n = 31)

0.24 (0.04–0.66)

0.125 (0.0–1.2)

0.31 (0.0–1.5)

0.25 (0.0–1.2)